,
Paula J. Hurley, Ph.D.

Assistant Professor
Hinman Urologic Education Endowed Fund Scholar

Department of Urology And Oncology
Johns Hopkins University School of Medicine
Address:
Cancer Research Building II, Room 154 1550 Orleans Street Baltimore, MD 21287

Office: 410-614-9453

Email: phurley2@jhmi.edu

Fax: 410-502-9453

The molecular basis of lethal prostate cancer

The goal of the Hurley laboratory is to reduce the death and suffering caused by aggressive prostate cancer.  To this end, the laboratory is focused on identifying novel genetic and molecular pathways driving lethal prostate cancer.  We recently identified SPARCL1 as a gene down-regulated in high-grade/ metastatic prostate cancer that is a significant, independent prognostic marker of disease progression to metastases.  The laboratory is currently examining the mechanistic roles of SPARCL1 and other mediators of aggressive prostate cancer.  In addition, the laboratory is also developing new methods for the early identification of drug resistance in metastatic patients using plasma tumor DNA and next generation technologies. 



Education


Year Degree/Certificate Institution Discipline
1997 B.A./Lawrence University       Biology
2004 Ph.D./University of Chicago School of Medicine Cancer Biology
2009 Post-Doctoral Fellowship/The Johns Hopkins School  Radiation Oncology


Publications


 Free access to abstracts at PubMed

Publications:  Peer-reviewed Original Science Research

  1. Boone DL, Lee EG, Libby S, Gibson PJ, Chien M, Chan F, Madonia M, Burkett PR, Ma A.  2002.  Recent advances in understanding NF-kappaB regulation.  Inflamm Bowel Dis.  May; 8(3):2001-12.
  2. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, Hurley PJ, Chien M, Chai S, Hitotsumatsu O, McNally E, Pickart C, and Ma A. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses.   Nat Immunol 2004; (10): 1052-60.
  3. Topaloglu O, Hurley PJ, Yildirim O, Civin CI, Bunz F.  Improved methods for the generation of human gene knockout and knockin cell lines. Nucleic Acids Res 2005; (18): e158.
  4. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, and Hwang PM. p53 regulates mitochondrial respiration. Science 2006; (5780): 1650-3.
  5. Hurley PJ, Wilsker D, Bunz F.  2007.  Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation.  Oncogene.
  6. Hurley PJ, Bunz F. 2007.  ATM and ATR:  components of an integrated circuit.  Cell Cycle. Feb 15; 6(4):414-7.
  7. Ross AE, Emadi A, Marchionni L, Hurley PJ, Simons BW, Schaeffer EM, Vuica-Ross M.  2011.  Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity.  BJU Int. Aug; 108(3):447-54.
  8. Ross AE, Marchionni L, Phillips TM, Miller RM, Hurley PJ, Simons BW, Salmasi AH, Schaeffer AJ, Gearhart JP, Schaeffer EM.  2011. Molecular effects of genistein on male urethral development.  J Urol. May; 185(5):1894-8.
  9.  Huang Z, Hurley PJ, Simons BW, Marchionni L, Berman DM, Ross AE, Schaeffer EM.  2012.  Sox9 is required for prostate development and prostate cancer initiation.  Oncotarget. Jul; 3(6):651-63.
  10. Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe S, Miller RM, Erho NG, Vergara IA, Ghadessi M, Huang Z, Gurel B, Park BH, Davicioni E, Jenkins RB, Platz EA, Berman DM, Schaeffer EM.  2012.  SPARCL1/Hevin is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome.  PNAS. Sep 109(37):14977-82. 
  11. Simons B, Hurley PJ, Berman DM, Schaeffer, EM.  2012.  Wnt Signaling Through Beta-catenin is Required for Prostate Lineage Specification.  Dev Biol. Nov; 371(2):  246-55.
  12. Beaver JA, Jelovac D, Balukrishna S, Cochran R, Croessmann S, Zabransky DJ, Wong HY, Toro PV, Cidado J, Blair BG, Chu D, Burns T, Higgins M, Stearns V, Jacobs L, Habibi M, Lange J, Hurley PJ, Lauring J, VanDenBerg D, Kessler J, Jeter S, Samuels ML, Maar D, Cope L, Cimino-Mathews A, Argani P, Wolff AC, Park BH.  2014.  Detection of Cancer Specific Mutations in Plasma of Early Stage Breast Cancer Patients.  Clinical Cancer Research.


Patents


2003    HCT-Chk2-/-p53-/- genetically engineered isogenic cell lines. 
Johns Hopkins Technology Transfer Reference Number C10803

2012    SPARCL1 and Metastatic Prostate Cancer.
Johns Hopkins Technology Transfer Reference Number C12106

2013    ASPN and Metastatic Prostate Cancer.
Johns Hopkins Technology Transfer Reference Number C12091

 



Membership


  • UNDER Construction


Awards & Honors


2014                Johns Hopkins Prostate Research Day Award, Johns Hopkins University
2013                Multi-Institutional Prostate SPORE meeting Poster Award – Fort Lauderdale, FL
2012                Johns Hopkins Cancer Research Day Award, Johns Hopkins University
2003                IBD Retreat Research Talk Award, University of Chicago
1997                Graduated Magna Cum Laude in academics, Lawrence University
1997                Graduated Magna Cum Laude in research, Lawrence University
1997                Phi Beta Kappa, Lawrence University